Literature DB >> 19449149

Secretory phospholipase A2 in patients with coronary artery disease.

Luciana Moreira Lima1, Maria das Graças Carvalho, Cirilo Pereira da Fonseca Neto, José Carlos Faria Garcia, Marinez Oliveira Sousa.   

Abstract

This study investigated the correlation of sPLA2 (secretory phospholipase A2) activity with the atheromatosis extent in subjects with coronary artery disease (CAD) undergoing coronary angiography. We analyzed 123 patients, including 35 subjects with angiographically normal coronary arteries (controls), 31 with mild/moderate atheromatosis (stenosis of 30-70% of the luminal diameter in one or more coronary arteries) and 57 with severe atheromatosis (>70% stenosis). Plasma sPLA2 activity was significantly higher in subjects with severe [127.7 U/ml (102.3-162.7); p < 0.0001] and mild/moderate [112.0 U/ml (100.6-146.9); p < 0.0001] atheromatosis than in controls [19.8 U/ml (15.1-32.1)]. In a multiple logistic regression model, adjusted for age, gender, body mass index, tabagism, hypertension, sedentarism, family history for coronary artery disease, diabetes mellitus, total cholesterol, HDLc, LDLc, triglycerides, high sensitivity C-reactive protein and phospholipase A2, only sPLA2 was observed to be independently associated with severe CAD (>70% of stenosis) (p < 0.0001).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449149     DOI: 10.1007/s11239-009-0345-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

Review 1.  Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.

Authors:  Krishnankutty Sudhir
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

2.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

3.  Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis.

Authors:  A Schiering; M Menschikowski; E Mueller; W Jaross
Journal:  Atherosclerosis       Date:  1999-05       Impact factor: 5.162

Review 4.  Phospholipase A(2) in vascular disease.

Authors:  E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal:  Circ Res       Date:  2001-08-17       Impact factor: 17.367

Review 5.  Secretory phospholipase A2 enzymes in atherogenesis.

Authors:  Nancy R Webb
Journal:  Curr Opin Lipidol       Date:  2005-06       Impact factor: 4.776

6.  Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.

Authors:  K Kugiyama; Y Ota; S Sugiyama; H Kawano; H Doi; H Soejima; S Miyamoto; H Ogawa; K Takazoe; H Yasue
Journal:  Am J Cardiol       Date:  2000-10-01       Impact factor: 2.778

Review 7.  Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Authors:  Carolina A Garza; Victor M Montori; Joseph P McConnell; Virend K Somers; Iftikhar J Kullo; Francisco Lopez-Jimenez
Journal:  Mayo Clin Proc       Date:  2007-02       Impact factor: 7.616

Review 8.  Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis.

Authors:  G Camejo; E Hurt-Camejo; O Wiklund; G Bondjers
Journal:  Atherosclerosis       Date:  1998-08       Impact factor: 5.162

9.  C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.

Authors:  Jian-Jun Li; Chun-Hong Fang
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

10.  Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium.

Authors:  Grietje Ch Beck; Benito A Yard; Jutta Schulte; Markus Haak; Klaus van Ackern; Fokko J van der Woude; Marietta Kaszkin
Journal:  Biochem Biophys Res Commun       Date:  2003-01-17       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.